Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.93, while Zimmer Biomet Holdings Inc trades at $93.05 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares MSCI United Kingdom (FTSE) pays none, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| EWU | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $107.71 |
52-Week Low | $39.80 | $79.58 |
Market Cap | — | $17.44B |
Enterprise Value | — | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $46.88, up 1.23% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The fund provides exposure to UK equities, which are influenced by rising oil prices and Middle East tensions, as highlighted in recent financial news. A dividend of $0.67 is scheduled for payment on June 18, 2026.
The outlook for EWU is cautiously optimistic, supported by technical strength and sector gains in energy. However, risks include geopolitical volatility and potential economic slowdowns in the UK. Investors should weigh the ETF's diversification benefits against exposure to regional uncertainties and currency fluctuations.
Zimmer Biomet (ZBH) trades at $92.94, up 2.1% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 70% gross margin and positive cash flow trends, though net income margin has declined from 13.8% in 2023 to 8.6% in 2025. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase, indicating management confidence.
ZBH presents a moderate growth opportunity with a consensus price target of $97.67, offering ~5% upside. Risks include rising debt levels and competitive pressures in medical devices. Analyst sentiment is mixed with 40% buy ratings, but institutional activity and strategic acquisitions support a stable outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
